Thursday, July 17, 2014
Publication and contact
expression to predict antidepressant treatment response
Cell culture and patient
sample studies suggest monitoring miR-1202 expression could help predict
response to antidepressants in patients with depression. In human prefrontal
cortex samples, miR-1202 levels were lower in patients with depression than
healthy controls. In human neural progenitor cells, chronic treatment with
the marketed antidepressants imipramine or Celexa
increased miR-1202 levels compared with no treatment. In blood samples from
patients with depression, miR-1202 expression was lower in remitter patients
than nonresponders and controls, and miR-1202 levels were higher in patients
after Celexa treatment than before treatment. Next steps could include
testing correlations of miR-1202 with other antidepressants and in wider
Imipramine is a generic tricyclic antidepressant.
Citalopram is a generic selective serotonin reuptake inhibitor and is
marketed by H.
Lundbeck A/S and Actavis
plc as Celexa.
Published online July 17, 2014
Patent and licensing status
Lopez, J.P. et al. Nat.
published online June 8, 2014;
Contact: Gustavo Turecki, McGill University, Montreal, Quebec,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]